Is Endothelial Nitric Oxide Synthase a Moonlighting Protein Whose Day Job is Cholesterol Sulfate Synthesis? Implications for Cholesterol Transport, Diabetes and Cardiovascular Disease by Seneff, Stephanie et al.
Entropy 2012, 14, 2492-2530; doi:10.3390/e14122492 
 
entropy 
ISSN 1099-4300 
www.mdpi.com/journal/entropy 
Review 
Is Endothelial Nitric Oxide Synthase a Moonlighting Protein 
Whose Day Job is Cholesterol Sulfate Synthesis? Implications 
for Cholesterol Transport, Diabetes and Cardiovascular Disease 
Stephanie Seneff 1,*, Ann Lauritzen 2, Robert Davidson 3 and Laurie Lentz-Marino 4 
1  Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, 
Cambridge, MA 01890, USA 
2 Independent Researcher, Houston, TX 77084, USA; E-Mail: crzdcmst@sbcglobal.net 
3 Internal Medicine Group Practice, PhyNet, Inc. Longview, TX 75605, USA;  
E-Mail: patrons99@yahoo.com 
4 Biochemistry Laboratory Director, Mount Holyoke College, South Hadley, MA 01075, USA;  
E-Mail: pcallist@yahoo.com 
* Author to whom correspondence should be addressed; E-Mail: Seneff@csail.mit.edu;  
Tel.: +1-617-253-0451. 
Received: 8 October 2012; in revised form: 28 November 2012 / Accepted: 4 December 2012 / 
Published: 7 December 2012 
 
Abstract: Theoretical inferences, based on biophysical, biochemical, and biosemiotic 
considerations, are related here to the pathogenesis of cardiovascular disease, diabetes, and 
other degenerative conditions. We suggest that the “daytime” job of endothelial nitric 
oxide synthase (eNOS), when sunlight is available, is to catalyze sulfate production. There 
is a striking alignment between cell types that produce either cholesterol sulfate or sulfated 
polysaccharides and those that contain eNOS. The signaling gas, nitric oxide, a well-
known product of eNOS, produces pathological effects not shared by hydrogen sulfide, 
a sulfur-based signaling gas. We propose that sulfate plays an essential role in HDL-A1 
cholesterol trafficking and in sulfation of heparan sulfate proteoglycans (HSPGs), both 
critical to lysosomal recycling (or disposal) of cellular debris. HSPGs are also crucial in 
glucose metabolism, protecting against diabetes, and in maintaining blood colloidal 
suspension and capillary flow, through systems dependent on water-structuring properties 
of sulfate, an anionic kosmotrope. When sunlight exposure is insufficient, lipids 
accumulate in the atheroma in order to supply cholesterol and sulfate to the heart, using a 
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process that depends upon inflammation. The inevitable conclusion is that dietary sulfur and 
adequate sunlight can help prevent heart disease, diabetes, and other disease conditions.  
Keywords: endothelial nitric oxide synthase; diabetes; cardiovascular disease; cholesterol 
sulfate; lysosomes; autophagy; heparan sulfate; hydrogen sulfide; nitric oxide; 
glycosaminoglycans 
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Abbreviations 
ADMA: asymmetrical dimethylarginine; Akt: protein kinase B (PKB); ATP: adenosine triphosphate 
BH4: tetrahydrobiopterin; Cbl: cobalamin; CblSSH: cobalamin persulfide; Ch-S: cholesterol sulfate; 
deoxyHb: deoxyhemoglobin; eNOS: endothelial nitric oxide synthase; ER: endoplasmic reticulum; 
EZ: exclusion zone; FAD: flavin adenine dinucleotide; FMN: flavin mononucleotide; GAG: 
glycosaminoglycan; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; Glc: glucose; GLUT: 
glucose transporter; GSH: glutathione; GSNO: S-nitrosylglutathione; GSSH: glutathione persulfide; 
Hb: hemoglobin; HDL: high-density lipoprotein; HMG-CoA reductase: 3-hydroxy-3-methyl-
glutaryl-Coenzyme A reductase; HS: heparan sulfate; HSPG: heparan sulfate proteoglycan; iNOS: 
inducible nitric oxide synthase; IR: infrared; LDH: lactate dehydrogenase; LDL: low-density 
lipoprotein; LRP: LDL receptor-related protein; LPS: lipopolysaccharide; metHb: methemoglobin; 
mTOR: mammalian target of rapamycin; mTORC1: mammalian target of rapamycin complex 1; 
NAc: N-acetyl; NAD(P): nicotinamide adenine dinucleotide (phosphate); NAD(P)H: nicotinamide 
adenine dinucleotide (phosphate), reduced form; NF-κB: nuclear factor κB; nNOS: neuronal nitric 
oxide synthase; NO: nitric oxide; oxyHb: oxyhemoglobin; PAPS: 3’-phosphadenosine-5’-
phosphosulfate; PFK: phosphofructokinase; PI3K: phosphatidylinositol-3-kinase; PKB: protein 
kinase B, also known as Akt; PKC: protein kinase C; PON1: paraoxonase 1; RBC: red blood cell; 
ROS: reactive oxygen species; SR: scavenger receptor; SULT: sulfotransferase. 
1. Introduction 
The nitric oxide synthases (NOSs) are a family of three distinct highly regulated isoforms of an 
enzyme class that produces nitric oxide (NO) [1,2]. The class consists of two constitutive forms, 
endothelial NOS (eNOS) and neuronal NOS (nNOS), which are activated by calcium-bound 
calmodulin, and an inducible form, iNOS, which is insensitive to calcium. eNOS, even when activated, 
produces only a small fraction of the amount of NO typically produced by iNOS. eNOS and nNOS are 
also capable of producing superoxide (O2−) in the absence of their substrate L-arginine, and this is 
generally viewed as a pathological response, although we will argue otherwise in this paper. 
Although eNOS is an extremely well-studied protein, much remains mysterious about its function. 
It is expressed not only in the endothelial cells lining blood vessel walls, but also in fibroblasts [3], 
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cardiomyocytes [4], platelets [5], and red blood cells (RBCs) [6], among others. It maintains a 
“resting” state bound to the protein caveolin in the small invaginations in the membrane surface known 
as caveolae associated with lipid rafts on the plasma membrane [4,7]. Lipid rafts are organized 
subdomains of the plasma membrane that are enriched in cholesterol and that play an important role in 
both signal transduction and nutrient transport across the membrane [8,9]. 
Caveolin-binding of eNOS disables NO synthesis. Activation of eNOS for NO production requires 
a complex sequence of events, beginning with calcium entry into the cell, followed by calcium binding 
to calmodulin, calmodulin binding to eNOS (triggering its disengagement from caveolin and the 
membrane), and phosphorylation of eNOS. Activation also requires the presence of tetrahydrobiopterin 
(BH4) as a cofactor, which increases the binding of the substrate, L-arginine [10]. When BH4 levels are 
low, or when L-arginine is unavailable, eNOS produces superoxide (O2−) instead of NO [11], due to an 
uncoupling mechanism. 
NO was the first signaling gas to be identified (others are CO and H2S). NO has diverse biological 
functions, some beneficial but others clearly pathological. NO induces relaxation of the artery wall via 
a guanylyl cyclase-dependent mechanism, and it promotes endothelial cell migration and 
neovascularization via activation of the phosphatidyl inositol 3 kinase (PI3K)/Akt pathway [12]. 
However, NO can react with superoxide to form the highly reactive agent, peroxynitrite (ONOO−). 
ONOO− is destructive to the iron-sulfur clusters associated with mitochondrial electron transport and 
DNA repair systems [13].  
A less well-known property of NO is its potent effect on glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), the rate-limiting enzyme in glycolysis. NO inactivates this enzyme through 
nitrosylation [14], causing it to migrate to the nucleus and activate synthesis of phase II detoxifying 
genes. The expression of these genes is associated with increased tumor resistance to several 
anticancer drugs [15]. Excess NO leads to the synthesis of S-nitrosoglutathione (GSNO) from 
glutathione (GSH) [16], which is metabolized to release ammonia, leading to increased permeability of 
the blood-brain barrier and toxic effects in the brain [17]. Perhaps the most disturbing aspect of NO is 
its negative effect on autophagy [18], which can lead to accumulation of toxic cellular debris, 
ultimately resulting in loss of cell viability. Impaired autophagy is a key factor in heart failure [19]. 
Here, we show that eNOS is a dual-purpose enzyme, i.e., a moonlighting enzyme [20], with 
complex signaling systems in place to control its switch between two distinct (and complementary) 
biological roles. One role is the synthesis of nitric oxide, which has already been well characterized. 
The other role, which we infer and document here, is the synthesis of sulfate from sulfane or sulfide 
sulfur and superoxide. In Section 3.2, we show how eNOS bound to caveolin at the plasma membrane 
can facilitate sulfate formation, provided sunlight is available. Sulfate enables cholesterol transport, 
and, furthermore, maintenance of sulfation in the extracellular matrix proteins is crucial for the health 
of the endothelial wall and of red blood cells and platelets. It has been established that insulin 
resistance and impaired autophagy can result from inadequate supply of cholesterol and sulfate to the 
plasma membrane and to lysosomes.  
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2. The Central Inference 
The novel inference, well supported by research cited in the following sections, is that cholesterol 
sulfate (Ch-S) deficiencies throughout the blood stream and the tissues can lead to diabetes and 
cardiovascular disease. Due to its amphiphilic character, Ch-S is able to supply both cholesterol and 
sulfate to tissues. The central theoretical inference is this: The "daylight job" of eNOS, mediated by 
sunlight exposure, is to synthesize Ch-S in the skin, while the “moonlighting job” switches to nitrate 
synthesis (via NO production) under adverse conditions (inadequate sunlight and/or insufficient 
membrane cholesterol).  
Heparan sulfate (HS) proteoglycans (HSPGs) play a central role. From the biosemiotic perspective, 
they control various signaling cascades [21], and respond differentially, depending upon the 
availability of cholesterol and sulfate. When sulfation levels are adequate, HSPGs temporarily buffer 
glucose, while protecting proteins from glycation damage. Thus, insufficient sulfate supply leads to 
insulin resistance. HSPGs in the glycocalyx stabilize the blood. Sulfate deficiencies therefore lead to 
increased risk of thrombosis and/or hemorrhage [22,23]. We suggest for the first time here, based on 
reasonable theoretical inferences from empirical research findings, that the atheroma in cardiovascular 
disease enables a repair system to synthesize both Ch-S and HS, alleviating deficiencies and protecting 
from thrombosis. Lysosomes, evolving from the budding-off of membrane caveolae, as is known, 
depend upon adequate supplies of both cholesterol and sulfate to function [24–29].  
Supporting the central inference about the switching of eNOS from its daylight to its moonlighting 
job; the Hofmeister series shows sulfate and nitrate as polar opposites with vastly different effects on 
local water structure. Nitric oxide interferes with autophagy [18]. It follows that a system based 
predominantly on nitrate derived from NO is not sustainable owing to cumulative impairment of 
lysosomal-based autophagy. Briefly put; cells would eventually be overwhelmed with their own debris.  
In Section 3 below, the many important functions of Ch-S are first presented. With those functions 
in mind, plausible processes by which eNOS can synthesize the sulfate associated with Ch-S are 
inferred and described. In Section 4, deficiency in the supply of Ch-S is shown to be a reasonable 
(though novel) explanation for the etiology of cardiovascular disease. The jumping off point for the 
reasoning leading to the conclusion about cardiovascular disease is the controversy surrounding the 
role of eNOS in red blood cells (RBCs). The surprising finding of research suggests that 
cardiovascular plaque can (serendipitously) synthesize Ch-S through an alternative pathway involving 
reactive oxygen species (ROS) in the artery wall. Our central thesis explains and expands on that 
unexpected finding. Section 5 discusses the Hofmeister series and some additional results on the 
effects of dissolved sulfate on water structure. Those results show why a cell must switch from sulfate 
synthesis to nitrate synthesis when membrane cholesterol is depleted. Section 6 discusses sulfated 
glycosaminoglycans (GAGs), and some of their known essential functions. Several cell types known to 
synthesize eNOS also have high demand for sulfate to produce sulfated polysaccharides. It follows that 
sulfate plays an essential role in the lysosomal breakdown of cellular debris. Section 7 discusses the 
three gasotransmitters, NO, CO, and H2S, emphasizing the fact that H2S does not react with superoxide to 
produce a highly reactive molecule, by contrast with the problematic formation of peroxynitrite from 
NO and superoxide. Section 8 discusses the role that NO plays in suppressing glycolysis and 
autophagy, resulting in impaired lysosomal processing. The final section offers some conclusions. 
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3. Cholesterol Sulfate and eNOS 
Cholesterol sulfate (Ch-S), a mysterious and poorly understood molecule, is constantly present in 
the blood plasma in small amounts with rapid turnover [30]. It is the most abundant of all the sterol 
sulfates in the blood, and the research we bring to bear shows that it provides colloidal stability to 
suspended particles and membrane stability to many cell types. Ch-S, in comparison to mere 
cholesterol, is amphiphilic, due in part to its negative charge, which imparts mobility through water-
based media such as the blood plasma and the cytoplasm. Ch-S is an overlooked supplier of both 
cholesterol and sulfate to lipoproteins and cells suspended in the blood and to all the tissues. When its 
supply is impaired, the tissues develop deficiencies in both cholesterol and sulfate. The remainder of 
this section first documents key functions of Ch-S, and then shows how eNOS attached to caveolae 
may produce Ch-S. A schema for an alternative mode of Ch-S production in the atheroma, one that 
invariably also induces inflammation in the artery wall, is also presented. 
3.1. Biological Roles for Cholesterol Sulfate 
Due to its ionic charge and amphiphilic property, Ch-S has a rate of inter-membrane exchange that 
is approximately ten times faster than that for cholesterol [31], allowing it to more readily enter plasma 
membranes. Cholesterol in the cell membrane plays a crucial role in protecting from membrane leaks [32]. 
A cell normally expends a significant portion of its ATP supply operating the Na/K-ATPase pump, 
which maintains the ion gradients for sodium and potassium [33]. These two ions, being in the first 
column of the periodic table, are very small, and therefore can readily migrate passively through the 
membrane, especially when cholesterol is depleted [34]. The chronic excess ion pumping in order to 
maintain the ionic gradient (high potassium concentration inside the cell, and high sodium 
concentration outside the cell) can exhaust the ATP supply chain, and impairment in the ATPase pump 
has been proposed to be a key early factor in many neurological diseases [35]. Most critically, free 
cholesterol is an essential component of lysosomal membranes, where it maintains low fluidity and 
reduces permeability to both potassium ions and protons [36,25], as well as maintaining osmotic 
stability [36]. Lysosomes are the highly acidic cellular organelles responsible for breakdown of 
endocytosed nutrients as well as cellular debris. Protection from proton leaks is essential for maintaining 
the low pH associated with lysosomes, required for the breakdown of metabolites. Loss of lysosomal 
membrane impermeability has been proposed as an early event in amyloid beta pathogenesis in 
Alzheimer’s disease [37] and in various related conditions (some of which we discuss in later sections). 
Sulfate also plays an essential role in lysosomes, initially bound to the polysaccharide chains of 
HSPGs, but ultimately detached from the sugars via a large number of different sulfatases that are 
localized to the lysosome [26]. Various lysosomal storage disorders related to genetically defective 
sulfatases are associated with severe physical and mental disabilities, attesting to the importance of 
these sulfatases, and therefore of the sulfates, for cellular viability [28,29]. Chondrocytes from animals 
with a dermatan sulfate storage disease related to impaired sulfatase function release nitric oxide and 
inflammatory cytokines, leading to degenerative joint disease [38]. These defective chondrocytes 
become filled with vacuoles containing undegraded chondroitin sulfate GAGs. 
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Ch-S is produced in large amounts in the epidermis, which, according to [30], is likely the major 
supplier to the blood stream. In X-linked ichthyosis, Ch-S accumulates in the skin, due to the defective 
steroid sulfatase associated with this disease. Both RBCs and platelets also produce Ch-S, which helps 
these cells maintain the negative charge that keeps them dispersed and protects from agglutination and 
thrombosis. Its presence in RBCs induces a change in shape from discoid to echinocytic, caused by the 
tendency of Ch-S to migrate to the outer membrane layer [39]. An impairment in such deformability 
due to glycated hemoglobin is associated with diabetes [40]. 
Ch-S plays a role in the maintenance of the skin barrier, by stimulating the production of 
profilaggrin [41]. Profillagrin is the precursor to filaggrin, the highly cross-linked protein that forms a 
tight mesh to maintain impermeability of the skin to water and microbes. Ichythosis results in atopic 
dermatitis due to impaired filaggrin function [42]. 
Leukotrienes are important mediators of the inflammatory response associated with asthma, 
atherosclerosis, and several types of cancer. It has been demonstrated that Ch-S suppresses the release 
of leukotrienes in neutrophils [43]. 
Ch-S plays an essential role in fertilization, as it is critically involved in the sperm capacitation 
stage that allows the sperm to fertilize the egg [44]. It also accumulates in high concentrations in the 
placental villi during the third trimester of pregnancy, likely supplying both cholesterol and sulfate to 
the fetus [45,46]. Both cholesterol and sulfate deficiencies are associated with autism [47,48]. 
3.2. How Might eNOS Synthesize Sulfate? Some Possibilities 
eNOS is an exceedingly complex and highly regulated enzyme [49]. eNOS consists of a 
homodimer, where each monomer contains two major regions, an N-terminal heme oxygenase domain 
and a C-terminal FMN/FAD binding reductase domain. The reductase domain is homologous to 
NADPH:cytochrome P450 reductase and similar flavoproteins. An interdomain linker provides a hinge 
which is modified from a closed position to an open position upon calmodulin binding. It has been 
proposed that the closed structure would support simultaneous two-electron transfer, whereas the open 
position favors one-electron transfer. It has been puzzling to researchers as to why eNOS requires such 
complexity and so much regulation [50]. If it is a dual-purpose enzyme, then the complexity can be 
explained as a constant need to determine whether it should synthesize sulfate or nitric oxide (which 
quickly reacts with oxygen to form nitrate [51] or with superoxide to form peroxynitrite [13]). 
One of the simplest life forms utilizes sulfur as a source of energy for metabolism, the sulfur 
metabolizing bacteria [52–54], famously known by their colorful hues in sulfur hot springs [55]. In 
fact, it has been hypothesized that the porphyrin ring in heme, an ancient biological molecular 
structure, was originally developed before the existence of an aerobic atmosphere, to support sulfur-
based electron transport [56]. Most photosynthetic bacteria can use a variety of inorganic sulfur 
compounds such as sulfide, elemental sulfur, polysulfides, thiosulfate, or sulfite as electron donors to 
grow photoautotrophically [57]. Several species of purple sulfur bacteria can also oxidize sulfur 
compounds to obtain energy as well as electrons for carbon dioxide reduction. 
In contrast with the vast number of microbial metabolic pathways reported for sulfate synthesis, the 
established routes by which humans and other mammals achieve this same end under normal,  
non-inflammatory conditions seem to be limited to catabolism of cysteine, via cysteine-sulfinate, to 
Entropy 2012, 14 2498 
 
 
pyruvate and sulfate [58] and mitochondrial conversion of H2S to thiosulfate, followed by oxidation to 
sulfite and sulfate [59,60]. There seems to be an additional, essential route for sulfate formation in 
humans: eNOS, which is predominantly expressed in cells that also make cholesterol sulfate, can 
catalyze the conversion of reduced sulfur to sulfate. 
In the remainder of this section, we justify certain additional inferences and testable hypotheses 
regarding possible substrates and mechanistic pathways for eNOS-catalyzed sulfate production. The 
ideas discussed have been partly inspired by studies on eNOS structure and function [1,11] and 
evidence on mitochondrial and microbial pathways for inorganic sulfur oxidation [59–62]. Testing 
these hypotheses will clearly require well-designed experiments featuring the following:  
(a) use of caveolin-bound, calmodulin-free eNOS;  
(b) use of various candidate reduced sulfur substrate compounds (see discussion below), preferably 
at physiologically-realistic concentrations;  
(c) activity assays aimed at detecting sulfate (not just NO); and  
(d) appropriate controls to suppress the facile non-enzymatic oxidation of reduced sulfur compounds 
in the presence of oxygen and trace metals [63].  
Candidates for entry-level substrates include thiols such as HS− and 3-mercaptopyruvate (3-MP), 
plus several sulfane sulfur species, including glutathione persulfide (GSSH), cobalamin persulfide 
(CblSSH), and thiosulfate (S2O32−). Most of these compounds figure prominently as starting points or 
intermediates in mitochondrial and microbial sulfur oxidation mechanisms [59–62]. However, 
inclusion of CblSSH in this list merits additional comment.  
Cobalamin, the heart of the vitamin B12 molecule, contains a cobalt cation embedded in a corrin 
ring, which is related to the heme group of hemoglobin. Our suggestion of CblSSH as a candidate 
substrate for eNOS-catalyzed sulfate synthesis is based on evidence that a reasonably stable cobalamin 
persulfide derivative can be prepared in aqueous solution at pH 7 [64]. Moreover, structural studies 
indicate that cobalamin, an inhibitor of NO synthesis, can fit well into the heme pocket of NOS 
isoforms [65]. In addition, a cobalt-phthalocyanine complex (a nitrogen-containing ring system 
comparable to a heme group) can facilitate photocatalyic oxidation of sulfur dioxide, in an aqueous 
environment, to produce sulfate. A two-electron transfer from sulfite leads to a Co(III)-sulfito-
superoxide complex, via a photo-assisted reaction on a titanium dioxide surface [66]. This aligns well 
with the two-electron transfer supported by eNOS in the closed hinge structure, when calmodulin is 
not present, as discussed above.  
We propose that one or more of these candidate substrates can transfer sulfur to a reactive cysteine (cys) 
residue in eNOS to form a cys-persulfide or, if thiosulfate is the substrate, a cys-thiosulfate 
intermediate, as schematized in Figure 1. Hydrolysis of the cys-thiosulfate moiety yields sulfate and 
cys-persulfide. eNOS contains a number of highly preserved reactive cys residues [11]. Likely 
candidates for participation in sulfate synthesis include cys-184, the axial ligand to the heme iron in the 
oxygenase domain, the cys-94 and cys-99 residues from each chain that form the Zn tetrathiolate 
group, or cys-689 and cys-908, located near the FAD- and FMN-binding regions. Cys-689 and cys-908 
have recently been shown to undergo S-glutathionylation by oxidized glutathione (GSSG), resulting in 
eNOS uncoupling and superoxide generation in the reductase domain [67,68]. 
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Figure 1. Potential substrates and intermediates for eNOS-catalyzed sulfate synthesis. See 
discussion in text. 
 
The next proposed step in our mechanistic scheme involves photocatalyzed reaction of the eNOS 
cys-persulfide intermediate with superoxide and water to generate sulfite and restore the cys residue to 
the thiol form (Figure 1). Sunlight may act directly to activate the water needed for this reaction, as 
discussed in Section 5 below. Additional assistance with electron transfer and superoxide formation 
may be provided by the Fe-heme group in the oxidase domain, the zinc from the Zn tetrathiolate group, 
the cobalamin moiety (in the case of a Cbl-SSH substrate), and/or the FMN-FAD electron transfer 
apparatus in the reductase domain (in the case of a glutathione persulfide substrate reacting with cys-689 
or cys-908). Sulfite can be further oxidized to sulfate by spontaneous reaction with oxygen or 
superoxide, or with assistance from heme-Fe(III)-O2 in the oxidase domain.  
As will be discussed further in Section 5 below, there are several ways in which water, with its 
special properties, may contribute to the “eNOS-catalyzed” synthesis of sulfate. Heterogeneous 
catalysis by the “on-water” effect that occurs at the interface of water and hydrophobic surfaces may 
stabilize the transition state(s) for the oxidation to sulfate [69]. An acidic pH afforded by the gel-like water 
exclusion zones (EZs) and Grotthuss-style “proton hopping” may further catalyze the oxidation [70]. 
Relative immobilization of substrates by long-range dynamic structuring of interfacial hydration water 
may also be operative [71,72]. The sulfate dianion has a long-range effect on water structure, and this 
effect is likely to be an important factor in its Hofmeister behavior [73].  
With regard to the union of sulfate with cholesterol to produce cholesterol sulfate, eNOS’s binding 
to caveolin is significant, because caveolin is also intimately involved in cholesterol transport both 
from HDL particles into cellular stores and from the endoplasmic reticulum (ER) to the plasma 
membrane [74]. Caveolin is therefore well positioned to bring cholesterol (whether retrieved from 
serum HDL or internally synthesized) into close proximity to sulfate synthesized by eNOS. The 
attachment of sulfate to cholesterol via the sulfotransferase SULT2B1b [75] requires an activation step 
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which consumes ATP to produce 3’-phosphoadenosine-5’-phosphosulfate (PAPS). As discussed later, 
ATP can be provided by glycolysis. It is reasonable to infer also that sulfation is an essential step in the 
transport of cholesterol from the Golgi apparatus to the plasma membrane. 
4. Red Blood Cells and Cardiovascular Disease 
According to the Framingham heart study [76,77], low cholesterol in HDL is the single strongest 
lipid predictor of cardiovascular disease. Furthermore, both cardiovascular disease and diabetes are 
associated with impaired zinc utilization and increased oxidative stress [78]. In a state of zinc 
deficiency, it follows that eNOS, which depends upon zinc, may provide insufficient sulfate, an 
essential mediator of cholesterol transport to HDL. As a consequence, superoxide, released into the 
vessel lumen, supports the synthesis of sulfate from homocysteine as a back-up supplier. This, then, 
can explain why homocysteine is a risk factor for cardiovascular disease [79]. 
Diabetes, also a known risk factor for cardiovascular disease, is associated with excess cholesterol 
in RBCs, leading to morphological changes and reduced deformability [40], thus impeding passage of 
RBCs through capillaries. Furthermore, a significant inverse correlation was found between RBC 
cholesterol content and serum ApoA1-HDL levels. This implies that the transporting of cholesterol 
from epidermal cells and RBCs to HDL-A1, as mediated by cholesterol sulfate, is impaired, leading to 
excess membrane cholesterol in these cells. Ordinarily, cells in the epidermis are major suppliers of 
cholesterol to HDL-A1. Due to the limited solubility of cholesterol esters in aqueous environments, 
cholesterol trafficking would be expected to require vesicular transport, yet no such vesicles have been 
identified [74]. Sulfation would solve the problem of cholesterol’s hydrophobicity, allowing it to 
traverse the water-based cytoplasm from the ER and/or Golgi bodies to the plasma membrane, and to 
travel from the plasma membrane through water-based blood to HDL-A1.  
The scavenger receptor, SR-BI, integrated into membrane caveolae, plays many roles in mediating 
cholesterol transport, as detailed in [80]. It is responsible for the uptake of oxidized or acetylated LDL 
by macrophages in cardiovascular plaque. However, it also binds HDL, and HDL outcompetes LDL 
when both are present in the medium. In the case of LDL, its binding leads to the endocytosis of the 
entire particle and subsequent processing in lysosomes. However, in the case of HDL, both free 
cholesterol from the lipid monolayer and cholesterol esters from the internal stores are transported into 
the cell, in a process termed “selective lipid uptake”. In [80], p. 794, it is stated, “The detailed 
molecular mechanism underlying SR-BI–mediated selective lipid uptake has not yet been elucidated.” 
The problem is lipid transport through water-based cytoplasm, one potentially solved through sulfation.  
Moreover, selective lipid uptake involving cholesterol sulfation is likely to be reversible, since 
macrophages deliver cholesterol to HDL particles via SR-BI, whereas steroidogenesis cells in the 
adrenal glands take up cholesterol from HDL particles via SR-BI for processing into steroids. 
Erythrocytes from mice with knock-out SR-BI function exhibit an irregular shape and macrocytosis, 
implying that RBCs make use of an SR-BI mediated mechanism as well. The presence of large 
autophagosomes in the defective erythrocytes implies impaired autophagy.  
Thus, it can be inferred that both cholesterol import as well as export depend upon sulfation. 
Caveolin binds to cholesterol esters and transports them from caveolae to intracellular membranes [74]. 
eNOS, also bound to caveolin, could provide the sulfate that imparts amphiphilic character to 
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cholesterol, thereby enabling cholesterol transport through the aqueous medium and facilitating 
systemic cholesterol bioavailability. One of the key features of cardiovascular disease is the 
accumulation of lipid-laden macrophages, which eventually succumb to excess cholesterol loading, leading 
to apoptosis. Macrophages in atherosclerotic plaque undergo apoptosis following excess accumulation 
of free cholesterol in the ER, which induces the unfolded protein response [81]. This is due in part to 
the inability to export cholesterol to HDL-A1 [82]. The key problem may be insufficient sulfate supply to 
alleviate their cholesterol burden. Blood sulfate levels may be biophysically-determined by the Jones-
Ray effect [83] and the long-range dynamic water structuring property of sulfate [73]. 
4.1. Red Blood Cells, eNOS and Cholesterol Sulfate 
Ever since it was discovered that RBCs contain eNOS, researchers have struggled to understand 
what function it could possibly serve in these cells [6,84,85]. It is chemically implausible that eNOS in 
RBCs could produce nitric oxide that would escape binding to the massive amounts of hemoglobin 
contained in RBCs. Binding to the iron in hemoglobin would render the hemoglobin inactive in 
oxygen transport, an effect that resembles the toxic effect of carbon monoxide. Thus, both the NO and 
the hemoglobin would be impaired in their normal function. Indeed, RBCs exhibit a very low rate of 
transport of the substrate L-arginine into the cell, and they contain a significant amount of the enzyme 
L-arginase, which degrades any L-arginine that manages to gain entry. It has been confirmed that 
erythrocytic NOS is inactive – that it is disabled in producing NO [85]. Furthermore, the eNOS in 
RBCs co-localizes with the plasma membrane [6], and it has been well established through studies on 
endothelial cells that membrane-bound eNOS is inactive with respect to NO synthesis. 
RBCs also contain a membrane-bound protein, band3, which binds, thereby inactivating, several 
enzymes involved with the glycolytic pathway, such as phosphofructokinase (PFK), aldolase, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and lactate dehydrogenase (LDH) [86,87]. 
Deoxyhemoglobin (deoxyHb) also binds to band3 and competes with the glycolytic enzymes, 
reactivating them by dislodging them from the membrane [88]. It has been argued in [86] that this 
technique of gathering the enzymes in an inactive state near the membrane allows them to become more 
concentrated once they are dislodged from the membrane by deoxyHb, thus increasing their reactivity. 
However, glycolytic enzymes are needed near the membrane to produce the ATP that can enable 
sulfate transfer to cholesterol. The sulfate dianion is assembled at the membrane by eNOS in the RBC, 
as previously discussed. Such a process can fixate oxygen and sulfur in the sulfate anion, and provides 
a second method besides oxyhemoglobin to transport oxygen. RBCs are among the short list of cell 
types that produce Ch-S [30], and we argue here that Ch-S synthesis is the main purpose of eNOS in 
RBCs, which explains its presence there. 
Ch-S also stabilizes the RBC membrane and protects it from hemolysis [89]. The concentration of 
Ch-S in RBC plasma membranes is approximately 2-fold higher than the concentration in blood 
plasma. We propose that the sulfate is first produced from thiosulfate or another form of sulfane sulfur 
by eNOS, with superoxide as a reactive intermediate (see Figure 1), and then reacts with ATP provided 
through glycolysis to form PAPS, which is subsequently used to produce Ch-S from cholesterol. PAPS 
is formed from ATP and sulfate, where one molecule of ATP is converted to pyrophosphate to activate 
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the reaction, and a second ATP molecule converts APS to PAPS by phosphorylation at the 3’ position. 
Glycolysis localized to the cytoplasmic area near the membrane can provide the ATP. 
In addition to its role in binding hemoglobin and glycolytic enzymes, band3 also plays an important 
role in the transport of anions across the membrane, and it has been shown that a chloride-sulfate 
exchange mediated by band3 is associated with the import of hydrogen ions, thus exporting the sulfate 
ions [90]. Since RBCs also export ATP [91], it becomes feasible to synthesize PAPS directly in the 
endothelial wall from ATP and sulfate. The PAPS, synthesized by endothelial cells, then becomes 
substrate for Ch-S synthesis by platelets adhering to the endothelial artery wall, as will be further 
discussed in section 4.3 on the atheroma. 
4.2. Nitrite-Induced Vasodilation by RBCs 
It has long been recognized that RBCs can enhance the vasodilation effects of serum nitric oxide, 
but most of the ideas developed to account for the mechanism are derailed by the problem of how to 
get the NO out of the RBC, as it will be quickly taken up by hemoglobin (Hb). The most plausible idea 
along these lines involves the reduction of nitrite back to NO under deoxygenated conditions. Nitrite 
reacts with deoxyHb to form various nitrosylated products [92], and it has been conjectured that these 
reaction products might bind to the RBC membrane and subsequently give up their bound NO to  
the bloodstream [93–97]. 
A more appealing solution has been proposed in [98], which elegantly bypasses the problem of the 
release of NO by RBCs by invoking a signaling mechanism involving ATP instead. These authors 
demonstrated that metHb, an oxidation product of oxyHb with nitrite, has a much higher affinity to the 
membrane than oxyHb. Furthermore, nitrite reaction products with deoxyHb have much higher affinity 
for the membrane than deoxyHb itself, which in turn has significantly greater affinity than oxyHb. 
Hence, under both oxygenated and deoxygenated conditions, Hb reaction with nitrite results in an 
increased tendency for Hb to bind to the membrane, displacing glycolytic enzymes and inducing 
glycolysis, thus generating ATP. The authors also showed that nitrite injection into plasma yielded a 
large increase in serum ATP, demonstrating that RBCs release the additional ATP into the medium. 
Finally, ATP reacts with purinergic receptors in the endothelium to directly stimulate NO synthesis by 
eNOS. Hence, this indirect mechanism leads to the observed increase in NO caused by RBCs. 
4.3. A Proposed Role for the Atheroma 
In this section, atherosclerosis, the inflammatory buildup of abnormal fatty deposits (atheromas) in 
the arteries, is considered as providing a serendipitous alternate route to Ch-S synthesis under 
conditions of sulfate deficiency. Specifically, homocysteine can provide a source of sulfate that 
becomes operative when the eNOS in RBCs, endothelial cells and platelets fails to produce adequate 
supplies of sulfate, likely due to deficiencies in zinc or cobalamin and/or to insufficient sunlight exposure. 
Like RBCs, platelets also inexplicably contain a functional eNOS [5], and they also produce  
Ch-S [99]. Platelets produce an abundance of Ch-S from cholesterol in the presence of PAPS. A quote 
from [99] captures the level of surprise that the researchers experienced in their experiments on 
platelets: “The remarkable increase in platelet cholesterol sulfate content (300-fold) after the addition 
of exogenous PAPS to the incubation medium was totally unexpected.” [99]  
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Chronically inflamed tissues support high levels of lymphocyte extravasation from the blood, and 
the initial adhesion of these immune cells to the vessel wall is mediated by selectins [100], whose 
ligands are sulfated sialomucins. In [101], it was demonstrated that endothelial cells in inflamed tissues 
possess active expression of the gene for ATP sulfurylase, which catalyzes the synthesis of PAPS from 
sulfate. This is viewed as a limiting step in the sulfation of selectin ligands, and so lymphocyte 
adhesion depends critically on the supply of PAPS by ATP sulfurylase. Thus, we conjecture that 
endothelial cells in the inflamed artery wall of atherosclerosis may be supplying PAPS to adhering 
platelets, utilizing as substrates sulfate and the ATP released by RBCs. 
Thus, both ATP and sulfate are needed for endothelial cells to produce PAPS, which can then be 
combined with cholesterol by platelets, using a sulfotransferase, to produce abundant Ch-S. This then 
provides another reason for RBCs to release ATP to the serum in the presence of nitrite–to provide 
substrate for PAPS synthesis by endothelial cells and subsequent Ch-S synthesis by platelets. Note that 
the presence of nitrite implies excess NO synthesis, which, in turn, reflects, according to our hypothesis, 
impaired sulfate synthesis by eNOS: eNOS has switched from sulfate to NO synthesis, and therefore 
the atheroma is tasked with supplying Ch-S. 
We therefore propose that a need for Ch-S synthesis by platelets may in fact be a controlling factor 
in atherogenesis, and that homocysteine, as a source of sulfate, can mediate this goal, but inflammation 
is necessary for the homocysteine-to-sulfate conversion to occur. Indeed, Ch-S has been shown to be 
present in atherosclerotic lesions [102]. Homocysteine, a strong risk factor for atherosclerosis [79], is 
associated with increased presence of ROS in the artery wall [103]. It has been demonstrated that 
excess homocysteine in the blood is converted into homocysteine thiolactone, which can become a 
source for sulfate in the presence of superoxide, with vitamins A and C serving as catalysts [104]. 
Since macrophages in the plaque readily take up cholesterol from oxidized small dense LDL 
particles (ox-LDL) and later release it into HDL-A1 [105,106], cholesterol would be available in the 
plaque to form Ch-S from PAPS, a service that would be performed by platelets trapped in the plaque. 
In [99], it was demonstrated that platelets will only accept cholesterol from HDL-A1 as a source for 
Ch-S synthesis–they reject not only all forms of LDL, but also other apolipoproteins bound to HDL 
such as apoE and apoA-II. 
Several lines of evidence point to the idea that homocysteine actively promotes the survival of O2− 
in the artery wall [107]. It does this in part by inhibiting the expression and secretion of antioxidant 
enzymes such as glutathione peroxidase (GPx) and superoxide dismutase (SOD) [108]. Homocysteine 
also inhibits the binding of SOD to the HSPGs at the surface of endothelial cells [109]. Finally, 
homocysteine activates cytokines such as nuclear factor B (NF-B) and protein kinase C (PKC) [110], 
which in turn upregulate NAD(P)H oxidase and NOS, further enhancing O2− production [111].  
In parallel, homocysteine upregulates expression of HMG-CoA reductase, increasing the 
biosynthesis and uptake of cholesterol [112], and thus enhancing the bioavailability of cholesterol to 
react with the PAPS that will be derived from homocysteine in the presence of O2− via the reaction 
presented in [104]. While these activities of homocysteine have in the past been viewed as 
pathological, a reinterpretation of the observed behavior suggests that, instead, such activities are 
essential for the establishment of a critically needed supply of cholesterol sulfate.  
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It has been proposed [113] that elevated homocysteine is a marker for elevated asymmetrical 
dimethylarginine (ADMA), a known marker of renal disease, and that ADMA, as an endogenous 
inhibitor of NO, is the true factor that negatively impacts heart health, since serum levels of 
homocysteine and ADMA are strongly correlated. In [114], it was shown that impaired supply of 
heparan-sulfate rich anionic sites in glomerular basement membranes is associated with congenital 
nephrotic syndrome, which is characterized by kidney failure and protein loss through urine. It is likely 
that severe sulfate deficiency in the glomeruli characterizes other forms of renal disease as well. 
Hence, suppressed synthesis of NO by eNOS due to excess ADMA would result in the synthesis of 
superoxide instead, due to uncoupling [115]. The superoxide would supply substrate for the reaction 
that leads to sulfate synthesis from homocysteine [104], which could then supply the glomeruli with 
sulfate and improve kidney function. Redirection of homocysteine towards methionine and 
methylation pathways through supplementation with vitamins B6, B12, and folic acid would reduce 
the bioavailability of homocysteine as a source of sulfate, thus impairing cholesterol sulfate synthesis 
in the artery wall and promoting further kidney failure, as well as further deficiencies in the supply of 
these critical nutrients to the heart. This could explain why trials attempting to lower serum 
homocysteine pharmacologically have met with little success in reducing heart disease risk [113]. 
Prostacyclin (PGI2) is a potent vasodilator and inhibitor of platelet aggregation. It also promotes an 
increased hydrolysis of cholesterol esters in smooth muscle cells, allowing the release of cholesterol to 
HDL-A1. Experiments have shown [116] that HDL-A1 prolongs the half-life of PGI2 from 5 minutes 
to 22 minutes. These authors showed that apo-A1 bound to HDL forms a complex with PGI2, thus 
delaying its degradation, and therefore promoting vasodilation and platelet stability. Apolipoproteins 
A-II, C-I, C-II, C-III, D and E, as well as LDL and Apo-A1 in isolation (not bound to HDL), did not 
possess this property. 
It has repeatedly been argued that HDL-A1’s benefit in cardiovascular disease is that it takes up 
cholesterol from macrophages in the plaque and returns it home to the liver. However, we propose 
instead that the benefit lies in its delivery of cholesterol to the platelets to promote the synthesis of Ch-S, 
in the presence of PAPS provided by homocysteine. This then explains the need for ROS in the artery 
wall, because homocysteine requires superoxide for sulfate production [104]. 
HDL's well-established protective role in cardiovascular disease is proposed to be partly due to the 
fact that it co-transports with paraoxonase 1 (PON-1), a potent antioxidant enzyme [117], which, 
however, is inactivated by oxidized LDL [118]. One of the key targets of PON-1 is homocysteine 
thiolactone [119]. PON1 possesses the ability to hydrolyze and therefore inactivate lactones, thus 
converting homocysteine thiolactone back to homocysteine [120]. PON-1 activity is inhibited through 
nitrosylation of ApoA-1 [121], so excess synthesis of nitric oxide would disrupt its function. 
Suppression of PON-1’s antioxidant effects would lead to enhanced superoxide production, and the 
increased bioavailability of homocysteine thiolactone will promote sulfate synthesis from the 
superoxide. Unfortunately, this will also expose the artery wall to oxidation damage, but ultimately 
enables the synthesis of Ch-S by platelets. 
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5. The Hofmeister Series, the Glycocalyx and the Effect of Sulfate on Water Structure 
There has recently been a resurging interest in the study of the unique properties of water, catalyzed 
in part by the efforts of Gerald Pollack to popularize this important concept [122]. In our research,  
we have come to realize that the unique ability of water to gel in the presence of certain solutes is 
essential to life.  
A careful examination of a living blood vessel, which is feasible by adding dyes and observing 
where they penetrate, reveals that there is a thick layer of impenetrable water surrounding the interior 
of the capillary wall [123]. Furthermore, this water is in a gel-like state, as it does not participate in the 
flow. Red blood cells remain in the center of the capillary, well separated from the physical wall of 
endothelial cells. This gel-like layer consists of water surrounding the glycocalyx, a layer of sulfated 
polymeric glycoproteins on the outer surface of most cells. The gel layer plays an essential role in 
maintaining blood flow and in protecting the endothelial wall [124]. The gel prevents the GAGs that 
are embedded within it from direct physical contact with the particles suspended in the blood. It also 
keeps out solutes, reducing the leakage of ions across the membranes of all the cells that are decorated 
with the GAGs, both those lining the capillary wall and those suspended in the blood. 
A key component of the glycocalyx is heparan sulfate, and it is the presence of sulfates in the 
heparan sulfate that maintains the gel, due to the physical properties of sulfate as a kosmotropic ion in 
the Hofmeister series [73,125,126]. By direct contrast, nitrate is a chaotrope–on the opposite end of the 
Hofmeister scale–and this distinction between nitrate and sulfate is likely a key reason why it is 
sulfates rather than nitrates that attach to the sugars in the glycocalyx. The Hofmeister series defines a 
continuum between the extremes of salting in and salting out, where chaotropes like nitrate promote 
disorder in the surrounding water and cause proteins to dissolve, whereas kosmotropes like sulfate 
promote a regular liquid-crystalline gel-like structure in the water and cause proteins to precipitate out. 
More importantly, anionic kosmotropes create an exclusion zone (EZ) in the water in their 
neighborhood, a region that is largely impenetrable both to dissolved ions and to suspended particles [127]. 
This exclusion zone is the gel that encases and protects the cell. 
Voeikov and Del Giudice [128] have pointed out the remarkable properties of such EZ water, in 
creating a negative electrical potential with regard to the bulk water adjacent to it (down to −150 mV), 
as well as a concentration of protons at the interface between EZ-water and bulk water. EZ water also 
absorbs light at 270 nm, and emits fluorescence when excited at this frequency. The thickness of the 
EZ water layer increases dramatically upon exposure to IR radiation [127]. 
In this context, it is interesting that eNOS attaches to the membrane at caveolae, and that HSPGs 
also attach at the lipid raft regions associated with the caveolae. According to [128], a key property of 
EZ water is the generation of electrons in a much higher state of excitation than normal, which can 
then presumably catalyze the reactions needed to oxidize thiosulfate to sulfate. They wrote: “As radiation, 
especially light in the IR part of the spectrum, increases the thickness of the layer of EZ-water, thereby 
increasing its electron-donating capacity, EZ-water becomes a practically inexhaustible source  
of electrons.” [128]. 
As a consequence of EZ’s surrounding sulfate molecules, the concentration of suspended particles 
and ions in the remaining bulk water is increased, and this is what leads to the property of salting out 
proteins–causing them to precipitate out of solution. We conjecture and will see later that the long-range 
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dynamic water-structuring property of sulfates and relatively weak magnetic field exposures [73,129] 
play an important role in concentrating enzymes in the lysosome to support the breakdown of proteins 
for recycling via heterogeneous “on-water” catalysis [69]. Both in the blood system and in the 
cytoplasm of individual cells, it is critical to maintain the proper balance of chaotropes and 
kosmotropes to support the proper folding and functioning of active proteins. 
Every cell suspended in the blood–the platelets, RBCs and white blood cells–is surrounded by a 
matrix of glycoproteins that maintains a negative charge and a kosmotropic water environment in order 
to protect the cell from aggregating with other cells in suspension and to minimize the rate of leakage 
of ions across the cell membrane. Through this strategy, the amount of energy needed to pump ions 
across the membrane in order to maintain, for example, a high internal concentration of potassium, is 
minimized. The sulfate ions in the GAGs are crucial for achieving this effect. 
Dianionic sulfate has long-range dynamic water-structuring properties [73], that protect from 
thrombophilia, a condition that is prevalent in the Western world, which manifests as an increased risk 
to thrombosis [130]. Sulfate deficiency is likely to lessen this water-structuring effect, throughout the 
entire vasculature. When sulfate is depleted, platelets will more readily activate, bind to fibrinogen, 
aggregate, and form blood clots, and cells will experience a depletion of their ATP levels as they are 
required to constantly maintain the Na/K-ATPase pump.  
Further support for our arguments concerning sulfate deficiency in the glycocalyx comes from the 
observation that hyaluronan overexpression is associated with both hypertrophic cardiomyopathy [131] 
and cardiovascular disease [132]. Hyaluronan is the only unsulfated glycosaminoglycan—it has an 
abundance of carboxylate groups instead, replacing the sulfates as kosmotropic anions. Hyaluronan is 
overexpressed specifically in the artery wall in the early stages of cardiovascular disease [132].  
6. Heparan Sulfate Proteoglycans 
Having presented above our hypotheses as to how an inadequate supply of cholesterol sulfate can 
give rise to heart disease, we will now consider how deficiency in another important set of biological 
sulfates–the heparan sulfate proteoglycans (HSPGs)–can lead to equally serious health problems. In 
this section, we will first discuss the extensive role that HSPGs play in regulatory systems in the cell. 
We then develop the novel hypothesis that HSPGs function as a temporary store for glucose, 
maintained just outside the cell, analogous to glycogen which stores glucose internally. We suggest 
that diabetes arises as a consequence of an impaired ability to produce HSPGs. Next, we mention 
briefly several distinct cell types that both contain eNOS and produce sulfated proteoglycans. Finally, 
we consider the essential role that HSPGs play in the lysosome, an organelle involved in the crucial 
process of breaking down accumulated cellular debris. This requirement for HSPGs in the lysosome 
implies that HSPG synthesis impairment leads to lysosomal impairment. 
6.1. Heparan Sulfate Proteoglycans and Glucose Metabolism 
Researchers have long been aware that all cells are decorated around their exterior wall by a 
collection of glycosaminoglycans (GAGs) generously modified by sulfate attachment, and often bound 
to membrane-associated proteins such as syndecans and glypicans [133]. However, it has only been in 
the last decade or so that an awareness has developed of the critical role these extracellular matrix 
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glycoproteins play in regulatory systems. Particularly noteworthy are the HSPGs, which consist of 
heparan sulfate polymers made up of glucose and galactose, modified by nitrogen (glucosamine, 
galactosamine) and by additional acetylation (N-acetylglucosamine) and/or O- or N-linked sulfation. 
Recently, the term heparanome has been used to characterize the repertoire of heparan sulfate sequence 
patterns associated with a particular cell type [134,135]. Researchers are only recently developing the 
necessary tools to be able to sequence the individual HSPG chains and experiment with genetic mutations 
in mice to try to determine more precisely the many roles they play in cell signaling systems [136]. 
The syndecans are cell surface proteins that regulate intracellular signaling as well as complex 
cellular activities such as adhesion, motility and invasion [137]. Syndecan shedding–the release of 
syndecan from the cell membrane into the interstitial spaces–is well-established as a pathological 
response associated with inflammation, microbial infection, and cancer [133,138–140]. High levels of 
shed syndecans in the blood plasma correlate with poor outcome in cancer patients [141,142]. Insulin 
induces a signaling cascade that results in the release of proteases that cleave the core protein of 
syndecan and induce shedding. Activation of protein tyrosine kinases leads to phosphorylation of the 
cytoplasmic domain, and subsequent shedding [143,144]. ROS also attack the syndecans, inducing 
shedding. Ch-S, on the other hand, is a potent inhibitor of proteases, including trypsin, chymotrypsin 
and elastase [145]. 
Recent research has revealed an important role for heparan sulfate in stabilizing syndecans on the 
cell surface [146]. In experiments involving several cell types, both normal and cancerous, depletion of 
heparan sulfate chains from the syndecan resulted in a 3- to 10-fold increase in the rate of syndecan 
shedding, depending on the cell type. Heparan sulfate depletion also stimulates the cell to increase the 
rate of syndecan synthesis, presumably to quickly replace the shed syndecans. Hence, heparan sulfate 
chains attached to syndecan play a crucial role in protecting the syndecan from destruction. It was 
hypothesized that the heparan sulfate chains form a physical barrier that protects the cleavage sites on 
syndecans, a hypothesis that aligns well with our proposal that sulfate forms solute-free exclusion 
zones in the surrounding water. 
Maintenance of a healthy intestinal epithelial barrier is essential for protection from influx of 
bacteria into the blood stream and subsequent sepsis. The heparan sulfate chains in syndecan-1 have 
been shown to be essential in maintaining a healthy barrier in both mice and humans [147]. Profound 
abnormalities in the GAGs, in both the connective and vascular tissues, have been found in association 
with colitis and Crohn’s disease [148], and this disruption likely is a significant factor in leaky gut 
syndrome. GAGs have also been shown to contribute to the pathology of rheumatoid arthritis and 
autoimmune disease [149]. In lupus nephritis, GAGs, and, specifically, heparan sulfate, are excreted in 
the urine [150]. Pancreatic beta cells produce an extraordinary amount of heparan sulfate, which 
protects them from damage due to ROS [151]. Heparan sulfate degradation by infiltrating immune 
cells is a mechanism for induction of type 1 diabetes. Furthermore, in type-1 diabetes, pancreatic beta 
cells are killed by activated macrophages, in part by the release of excess NO [152]. 
One hypothesis regarding cardiovascular disease is that the damage to the vasculature accrues 
mainly as a consequence of cytotoxins resulting from an immune response to infective agents known 
to be present in the plaque [153]. The most common such agent is Chlamydia pneumoniae [154,155]. 
Chlamydia pneumoniae can only grow and survive inside a host cell, where it accumulates in vacuolae 
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and produces a glycosaminoglycan which bears an extremely strong resemblance to heparan sulfate [156]. 
We hypothesize that C. pneumoniae may be playing a protective role in providing heparan sulfate to 
the vasculature. Indeed, attempts to treat cardiovascular disease with antibiotics have met with failure, 
the treated group suffered increased cardiovascular mortality compared to the control [157]. An 
explanation could be that the microbes are assisting in the task of maintaining heparan sulfate supplies.  
Aberrant insulin receptor signaling has been proposed as a major contributor to the oxidative stress 
associated with aging [158], and we suggest that this impairment may be attributed to impaired 
heparan sulfate synthesis. People with diabetes are at high risk of developing nephropathy, leading to 
proteinurea and, ultimately, renal failure. Heparan sulfate constitutes over 80% of the proteoglycans in 
the glomeruli basement membrane of the kidneys [159]. Diabetes is associated with a reduction in 
heparan sulfate levels in the glomerular matrix proteins in both humans [160] and rats [161]. In [162], 
it was shown that, following exposure to high serum glucose, there is a marked reduction in the 
incorporation of glucosamine into GAG chains, with an associated reduction in the biosynthesis of 
sulfated GAGs, in the glomerular endothelial glycocalyx. This suggests a link between high serum glucose 
and impaired GAG synthesis in the kidneys, likely due to glycation damage to glycolytic enzymes. 
HSPGs have a very rapid turnover rate–it is estimated that they are recycled with a half-life of 1 to 
4 hours [135]. Since glucose is a core component, it is tempting to speculate that one role HSPGs 
might serve is as a temporary storage site for glucose, analogous to glycogen. We hypothesize that the 
sulfate moiety serves an essential role as a mechanism to assure that the glucose is inert in the 
extracellular environment–similar to the phosphorylation step that initiates glycolysis. Both sulfate and 
phosphate are anionic kosmotropes [163], which, we propose, would have the effect of forming an EZ 
in the vicinity of any sulfate unit, thus protecting blood proteins from glycation damage. Such a mechanism 
would facilitate glucose metabolism, where excess dietary glucose could be temporarily housed in the 
HSPGs, and later metabolized after the breakdown of the HSPGs in the endosome and lysosome.  
This process would become impaired if insufficient sulfate is available. The result, we propose, 
would be the build-up of O-linked N-acetylglucosamine (O-Glc-NAc) modified proteins in the 
cytoplasm and the nucleus [164]. It is informative to examine glucose metabolism in skeletal muscle 
cells, which are the key cell type that becomes impaired in glucose uptake in association with type-2 
diabetes. A revealing study involved mice that overexpressed glucose transporter GLUT1, the GLUT 
that controls basal glucose uptake in muscle cells [165]. Muscle cells also utilize GLUT4, which 
migrates to the membrane at lipid raft domains in response to insulin signaling, and whose function is 
impaired in diabetes. The mice with overexpression of GLUT1 exhibited impaired GLUT4 activity, 
which was associated with O-Glc-NAc binding to GLUT4. Type 2 diabetes is associated with excess 
O-Glc-NAc binding to cytoplasmic proteins [166], which, we propose, is due to impaired GLUT4 
signaling as a consequence of both depleted cholesterol, resulting in a reduced number of lipid rafts 
(the locale where HSPGs bind and where GLUT4-mediated glucose uptake takes place), and depleted 
sulfate, resulting in a reduced ability to produce functional HSPGs. Hence the glucose must be 
immediately processed and the excess is converted to O-Glc-NAc, affecting cellular proteins. 
There is an interesting link between excess glucose and homocysteine thiolactone synthesis 
mediated by methionyl-tRNA synthetase. Mammalian systems are similar to E. coli with respect to the 
role that methionyl-tRNA synthetase plays in methionine incorporation into proteins [167]. Studies on 
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E. coli have demonstrated that, due to competition of homocysteine with methionine in the process that 
assembles amino acid chains, one molecule of homocysteine is edited to produce homocysteine 
thiolactone per 109 molecules of methionine incorporated into protein in vivo [168]. Thus, an excess 
need for protein synthesis would lead to an excess synthesis of homocysteine thiolactone. Excess 
protein synthesis is expected when proteins are disrupted by glycation damage, which would be 
predicted to occur when there is insufficient sulfate to properly store glucose in HSPGs. This 
conveniently leads to an overproduction of homocysteine thiolactone, now available as substrate for 
sulfate synthesis, precisely when sulfate is needed, as indicated by excess glycation damage. 
HSPGs can entrap a wide variety of extracellular effectors [169], particularly those associated with 
the LDL receptor-related protein (LRP) [170]. The LRP controls endocytosis of a remarkable range of 
proteins, related to blood platelet stability, cholesterol uptake, proteinases and their inhibitors, 
lysosomal enzyme activation, signal transduction, and neurotransmission [171]. HSPGs bind 
preferentially to the regions surrounding the lipid rafts [143,144], and these are also the areas where 
glucose enters the cell, mediated by GLUT4. HSPGs also bind growth factors like fibroblast growth 
factor (FGF), which are involved in promoting angiogenesis and neuronal development [172], and this 
binding too is mediated through lipid rafts [173]. 
Thus we propose that cholesterol depletion would reduce the availability of lipid rafts, and sulfate 
depletion would disrupt the ability to safely incorporate glucose into HS chains–both of these effects 
would contribute to insulin resistance in skeletal muscle cells and resulting type-2 diabetes. Both 
cholesterol and sulfate depletion would be traced back to the insufficient production of Ch-S in the 
skin in response to sunlight exposure. 
6.2. eNOS and Sulfated Glycosaminoglycan Synthesis 
We have identified at least five cell types, all of which contain either nNOS or eNOS, and all of 
which are also responsible for the synthesis of numerous highly sulfated glycosaminoglycans. In each 
example below, we argue that the main function of their NOS enzyme is to produce sulfate to supply 
the GAG chain: 
Endothelial Cells: Endothelial cells are the site where eNOS was first identified, which explains the 
nomenclature of the enzyme. Endothelial cells are tasked with maintaining and constantly renewing 
the endothelial glycocalyx, a thick wall of sulfated proteoglycans [174]. The glycocalyx is a dynamic 
structure with constant turnover, due to degradation by matrix metalloproteinases or shedding due to redox 
stress or shear stress. Hence, there is a constant need for sulfate to renew the supply to the glycocalyx. 
Fibroblasts: Fibroblasts, cells whose sole responsibility is to synthesize extracellular matrix and 
collagen, contain both eNOS and nNOS [175,3]. Fibroblasts are responsible for synthesizing HS, 
dermatan sulfate, and chondroitin sulfate, all of which contribute to the extracellular matrix proteins 
that decorate the exterior of essentially all cells [176]. Thus fibroblasts have an abundant need for a 
steady supply of sulfate to perform their normal functions. 
Pancreatic β Cells: Pancreatic β cells express an unusually low level of most common free radical 
scavenger enzymes, yet they suffer significant exposure to oxidizing agents associated with the 
synthesis and release of insulin. They maintain a huge and unusual cytoplasmic store of HS for 
protection from oxidative damage [151]. β cells also contain a functioning nNOS [177], and so they 
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may use this synthase to produce sulfate to supply their internal stores. It is unlikely that they use it to 
produce NO, as they are highly sensitive to NO, and it has been demonstrated that exposure of β cells 
to NO produced by macrophages kills them, leading to type-1 diabetes [178]. 
Mast Cells: Mast cells, which mediate emergency reactions, contain a functional eNOS, whose 
expression pattern is increased after ischemia [179]. The eNOS was localized mainly to the granules of 
activated mast cells. Mast cells release heparin stores from secretory granules into the artery wall 
during stress conditions, and heparin, a free-standing glycosaminoglycan, is the most highly sulfated 
molecule known to biology. Again, if the eNOS can synthesize sulfate, then it can supply sulfate to 
produce heparin. 
Neurons: eNOS is present in the neurite outgrowth of neurons, where its role is poorly understood. 
Neurite outgrowth depends upon ATP produced by glycolysis, which is actively suppressed by nitric 
oxide [180]. On the other hand, heparan sulfate plays an essential role in neurite outgrowth; several 
different sulfated glycosaminoglycans will stimulate growth-factor induced neurite outgrowth [181], 
and heparan sulfate supplied to the medium stimulates neurite outgrowth even in the absence of growth 
factors [182]. Once again, there is a compelling reason to produce sulfate, and clear justification not to 
produce nitric oxide. 
6.3. The Lysosomal Connection 
Lysosomes are cellular organelles that enzymatically degrade accumulating cellular debris. The 
lysosome also plays an essential role in degrading the cell walls of invasive microbes, i.e., 
lipopolysaccharide (LPS). Multiple lysosomal storage diseases involving impaired sulfate metabolism 
point to the importance of sulfate for proper lysosomal function [183]. Following endocytosis, 
syndecans undergo core protein proteolysis and glycosaminoglycan chain fragmentation in endosomes, 
and the remaining glycosaminoglycan fragments are fully degraded in lysosomes, a process that is 
impaired in many types of tumor cells [184]. The process of breaking down sulfated 
glycosaminoglycans is described in detail in [38]. The glycosaminoglycan chains are separated from 
the protein core but maintained intact until all the protein has been degraded. Subsequently, the chains 
are first broken up into much smaller units before the sulfate is stripped off.  
We propose that the sulfated GAGs facilitate the action of the enzymes involved in protein 
degradation. This is due in part to the kosmotropic property of sulfate [73]. We hypothesize that this 
effect creates exclusion zones of structured water surrounding the sulfate ion, effectively increasing the 
acidity of the remaining bulk water and increasing the concentration of the proteins and enzymes in the 
excluded regions, thus enhancing reactivity. As mentioned previously, the lysosome also depends 
crucially on adequate cholesterol to prevent proton leaks from disrupting its required acidic 
environment [25,36].  
7. Signaling Gases: H2S, NO and CO 
Nitric oxide was the first gas to be identified as a signaling molecule, leading to vascular dilation 
mediated by guanylyl cyclase [185]. Subsequently, both hydrogen sulfide (H2S) and carbon  
monoxide (CO) were found to play a similar role in influencing vascular dilation and inducing oxygen 
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flow through the arteries [186]. It is intriguing to think of each of these gases and their capability of 
binding oxygen, as illustrated in Table 1. 
Table 1. Oxidation of signaling gases to oxidation products. 
2H2S  S2O32-  2SO42- 
  NO  NO32- 
  CO  CO32- 
Both CO and NO are rapidly and spontaneously oxidized by oxygen, which then leads to ionic 
buffering of CO32− and NO32− in the blood stream. The pathway from H2S to sulfate is more complex 
and less clear; indeed, multiple routes may be possible. We have proposed in Section 3.2 that HS− may 
be a direct substrate for eNOS-catalyzed sulfate production. Alternatively, H2S could first be oxidized 
in the mitochondria to thiosulfate (mitochondria will avidly take up H2S and produce ATP via the 
ensuing oxidative reaction [187]). Thiosulfate can then be further oxidized to yield two sulfate anions, 
through the enzymatic action of eNOS or nNOS, with sunlight activating the reaction, as described  
in Section 3.2.  
H2S appears to have all of the benefits of NO with none of the adverse effects. Like NO, H2S 
relaxes smooth muscle cells, inducing vasorelaxation [188]. In the brain, H2S facilitates long term 
potentiation, enhances synaptic transmission, and protects neurons from oxidative stress [189]. H2S 
exhibits powerful anti-inflammatory, cytoprotective, immunomodulating, and trophic effects on the 
vast majority of normal cells, while at the same time exhibiting pro-apoptotic and pro-oxidant effects 
on malignant cells [190]. In experiments with lipopolysaccharide-stimulated macrophages, it was shown 
that H2S inhibits NO production and NF-κB activation, via a mechanism that involves activation of 
heme oxygenase-1 [191]. NF-κB plays a central role in the inflammatory response that underlies many 
autoimmune diseases such as rheumatoid arthritis, type-1 diabetes and Crohn's disease [192,193]. 
H2S prevents mitochondrial dysfunction caused by the pesticide rotenone, which would otherwise 
lead to apoptosis [194]. We propose that this is due to the fact that SO42- can be a substrate for taurine 
synthesis [195], and taurine plays a protective role in mitochondria through taurine modification of 
mitochondrial RNA [196]. Taurine has a pKa value in the range of 8.6 to 9.0 [197], which makes it an 
excellent candidate for pH buffering in the mitochondria, in order to maintain their basic pH range 
from 7.5 to 8.5. And, indeed, it has been demonstrated that taurine is present in significant 
concentrations in the mitochondria of muscle cells. This provides a plausible reason for eNOS to 
produce sulfate from the thiosulfate that is the product of oxidation of H2S in the mitochondria. 
8. NO and Autophagy Suppression 
GAPDH catalyzes the final and rate-limiting step in glycolysis. The GAPDH tetramer contains 16 
free thiols, including 4 active site thiols. NO inhibits the activity of GAPDH by nitrosylating one or 
more of its active site thiols, and this prevents them from oxidizing to sulfenic acid [198]. During 
glycolysis, NAD+ is reduced to NADH. NO inhibition of glycolysis causes a favoring of the pentose 
phosphate shunt for cytoplasmic glucose metabolism, an anabolic pathway that reduces NADP+ rather 
than NAD+. This has the convenient effect of renewing NADPH that is being oxidized during the 
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process of synthesizing NO using eNOS. Thus glycolysis inhibition replenishes NADPH for further 
NO production. 
However, GAPDH stimulates autophagy, the process by which a cell clears and recycles debris 
accumulating from misfolded proteins [199,200]. Autophagy is also essential for cellular health by 
means of removing dysfunctional cellular organelles, such as mitochondria and ER [201,158]. 
Furthermore, autophagy has recently been found to be intimately involved in the efflux of cholesterol 
from macrophage foam cells to HDL-A1, and defects in such efflux are believed to be a critical factor 
in cardiovascular disease [202]. In [203], severe autophagy derangement was observed in connection 
with heart failure, where individual cardiomyocytes were filled almost entirely with autophagic 
vacuoles. This suggests that impaired autophagy plays an important role in the pathology of heart failure. 
By inhibiting glycolysis, NO also inhibits autophagy. In fact, NO inhibits autophagy through other 
systems as well. Mammalian autophagy is regulated by a serine-threonine kinase called mammalian 
target of rapamycin (mTOR) [158,204], where the formation of a complex, mTORC1 inhibits 
autophagy. NO not only activates mTORC1 but also impairs the formation of the autophagy initiation 
complex, in addition to its effects on GAPDH [18]. Autophagy inhibition may account for 
accumulations of aggregated proteins due to nitrosative stress in neurodegenerative diseases. Insulin 
resistance is associated with impaired removal of defective mitochondria in cultured hepatocytes, due 
to suppression of autophagy [205]. 
Why might it be important to inhibit autophagy when NO is present? We believe this reflects the 
duality of eNOS, that it cannot produce sulfate if it is producing NO. As we discussed previously, the 
breakdown of proteins in the lysosome depends upon an adequate supply of HS, which is no longer 
being renewed when glycolysis is suppressed, because glycolysis provides the ATP that activates 
sulfate through the formation of PAPS. Furthermore, eNOS is not producing the sulfate needed for 
PAPS synthesis. So the renewal of HSPGs is disrupted, and therefore processes that would depend 
upon, and therefore consume, HSPGs must be avoided. 
9. Discussion 
In this paper, we have developed a novel hypothesis that cardiovascular disease and diabetes may 
be caused in part by a deficiency in the supply of cholesterol sulfate to the vasculature and to the 
tissues. We propose that eNOS, well established in the role of synthesizing NO, is a dual-purpose 
enzyme, and that its more important role is to synthesize sulfate from sulfane or sulfide sulfur and 
superoxide. Further, the synthesized sulfate immediately reacts with ATP to produce PAPS, where 
glycolysis provides the necessary ATP. PAPS then serves as a sulfate donor for at least two important 
molecules: Ch-S and HSPGs. We also argue that sunlight exposure to the skin is a catalyst for sulfate 
synthesis, and, therefore, that insufficient sunlight exposure is a risk factor for diabetes and heart 
disease. We hypothesize that both of these conditions evolve from a widespread deficiency in both 
cholesterol and sulfate throughout the tissues. Due to the broad scope of the paper, we have been 
restricted to covering each topic at a superficial level, but the referenced literature can fill in the details. 
An important contribution of this paper is the novel idea that HSPGs provide a beneficial 
mechanism to buffer glucose, where sulfation is crucial in preventing the glucose from reacting with 
serum proteins, resulting in glycation damage, an argument that we support from the literature on 
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structured water and exclusion zones [122–130]. The inferences drawn here, if valid, explain the 
known link between diabetes and cardiovascular disease. The important physical properties of  
sulfate–an anionic kosmotrope–create an exclusion zone of structured water surrounding the HSPGs, 
which permits them to temporarily retain glucose outside the cell without risk of uncontrolled and 
undesirable reactions. The rapid turnover rate of HSPGs supports their role as a buffer for glucose 
storage. The later metabolism of HSPGs takes place in the lysosome, and plays a crucial role in 
autophagy to recycle cellular debris. An impairment in this renewal process for HSPGs leads to excess 
serum glucose, a hallmark of insulin resistance, as well as impaired efflux of cholesterol from foam 
cells, a hallmark of cardiovascular disease. 
Another contribution is the idea that the build-up of cholesterol in the atheroma associated with 
cardiovascular disease follows naturally as a consequence of severe Ch-S and HSPG deficiency [99–121]. 
We show how macrophages and platelets can work together in the plaque to extract cholesterol from 
damaged small dense LDL particles and export it into HDL-A1, and then to use the HDL-A1 
cholesterol as a source for Ch-S. Homocysteine thiolactone provides the sulfate, which requires 
inflammation (inducing superoxide) to catalyze the reaction. RBCs export ATP to support the 
conversion of sulfate to PAPS. Platelets perform the final step of producing Ch-S within the 
extracellular matrix of the atheroma [99]. Inflammation has long been recognized as a critical factor in 
cardiovascular disease [206], and our view is that a key inflammatory agent, superoxide, is needed as 
substrate to produce sulfate from homocysteine thiolactone [104]. Furthermore, C. pneumoniae, by 
invading the artery wall, can function to replenish heparan sulfate supplies [154,155], providing a 
positive role for infection in cardiovascular disease.  
Na/K-ATPase plays a pivotal role in the pathology associated with excess NO synthesis by eNOS. 
A complex interplay among Na/K-ATPase, caveolin-1, and cholesterol alters the structure and function 
of the plasma membrane. High membrane cholesterol inhibits the ATPase activity of the Na/K-ATPase 
pump, and low membrane cholesterol activates it [34,207]. 
A subsequent reduction in the number of lipid rafts (where caveolin is localized) will also disrupt 
eNOS’ ability to synthesize sulfate, thus impairing the ability of HSPGs to store buffered glucose. The 
consequence of the excess accumulation of sodium in the cell due to the abandoned pump is an 
increased operation of the sodium-calcium exchanger, leading to a build-up in calcium and the 
resulting switch for eNOS from sulfate synthesis to nitrate synthesis (via NO). This switch is now 
imperative, because the switch from potassium (a chaotrope) to calcium (a kosmotrope) requires a 
reverse switch from sulfate (a kosmotrope) to nitrate (a chaotrope) to compensate. Statin drugs have 
recently been shown to increase the calcium burden in calcified plaque [208], and this can be easily 
explained as a consequence of loss of cholesterol in plasma membranes. 
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Figure 2. Schematic of two different systems for eNOS-Cav at the plasma membrane 
versus eNOS-CaM acting in the cytoplasm, for an endothelial cell. (a) In the healthy state, 
membrane-bound eNOS produces sulfate, which reacts with ATP to produce PAPS, the 
substrate for sulfation of HSPGs in the Golgi body. The ATP is provided by glycolysis, 
with GAPDH being the rate-limiting enzyme. NAD+ is reduced during glycolysis, and 
restored through the conversion of pyruvate to lactate, among other possibilities.  
(b) Cytoplasmic eNOS produces both superoxide and nitric oxide. NADPH is oxidized 
during NO synthesis, and restored via the pentose phosphate shunt. Superoxide is a key 
source of ROS in the artery wall associated with cardiovascular disease. 
 
Figures 2 and 3 schematize our view of two distinct configurations for metabolism of glucose in the 
endothelial cells (Figure 2) and the RBCs (Figure 3), respectively, depending upon the bioavailability 
of eNOS-derived sulfate. In the endothelial cell, low membrane cholesterol and depleted HSPGs lead 
to calcium influx and a switch from sulfate to NO synthesis by eNOS, with a concurrent switch from 
glycolysis to the pentose phosphate shunt for glucose metabolism. The pentose-phosphate shunt will 
renew the NADPH needed for NO synthesis, but a defective glycocalyx will persist since HSPG 
synthesis from eNOS-derived sulfate and ATP is no longer available. The RBC responds differently, 
due largely to the high concentration of Hb in the cytoplasm. Displacement of glycolysis enzymes 
from band3 by nitrosylated Hb leads to increased glycolysis upon exposure to high concentrations of 
serum NO, and simultaneously the export of ATP is also enhanced, deflected away from cell-internal 
Ch-S synthesis. ATP released into the artery wall will supply substrate for PAPS synthesis from 
homocysteine in the developing atheroma. In theory, this would indirectly restore the Ch-S supply, 
thus leading to repair of the endothelial glycocalyx. 
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Figure 3. Schematic of the response of the RBC to NO exposure. (a) In the healthy state, 
membrane-bound eNOS produces sulfate, which reacts with ATP to produce PAPS, the 
substrate for sulfation of both cholesterol and HSPGs in the Golgi body. The ATP is 
provided by glycolysis. Deoxy-Hb displaces glycolytic enzymes from the membrane to 
activate them. (b) NO infiltrates the cell and reacts with Hb to form nitrosylated complexes 
that further displace glycolytic enzymes from the membrane and induce both additional 
ATP synthesis and export of ATP to the blood stream. eNOS is dislodged from the 
membrane and can no longer produce sulfate. The exported ATP can provide substrate for 
PAPS synthesis from sulfate derived from homocysteine in the atheroma. 
 
The fact that NO inhibits autophagy is disturbing. Autophagy protects organisms against diverse 
pathologies, including infections, cancer, neurodegeneration, aging, and heart disease [198–205], and 
impairments in autophagolysosomal maturation are associated with Alzheimer’s disease [209]. Since 
autophagy depends upon both cholesterol and sulfate in the lysosome, NO inhibition of autophagy is 
an appropriate response, as our hypothesis implies that the presence of NO is an indicator of impaired 
Ch-S synthesis. However, long-term sustained NO synthesis by eNOS at the expense of sulfate will 
lead to a build-up of damaged organelles such as mitochondria and ER, as well as glycated and/or 
misfolded proteins, resulting in the unfolded protein response and subsequent apoptosis [210].  
An investigation of the relationship between geography and heart disease identified a linear 
relationship between latitude and serum cholesterol levels, as well as an inverse linear relationship 
between sunshine per year (based on weather records) and death from cardiovascular disease among 
men [211]. The authors proposed that the high rate of coronary heart disease in the British Isles could 
be due to the combination of a high latitude and high cloud cover. While the benefits of sun exposure 
have always been attributed to vitamin D3, we propose here that the true benefit instead is Ch-S 
Entropy 2012, 14 2516 
 
 
production in the skin. Interestingly, the vitamin D3 that is produced in the skin is also sulfated, and 
we suggest that vitamin D3 sulfate may be beneficial as a Ch-S mimetic. The sulfated form of vitamin 
D3 is inactive for calcium transport. We further suggest that this distinction may explain the failure of 
placebo-controlled experiments using unsulfated vitamin D3 supplements to show clear benefit in 
cardiovascular disease [212]. 
Recently, the sunscreen industry has been promoting full spectrum sunscreens, which contain active 
ingredients such as zinc oxide or titanium dioxide, along with an aluminum hydroxide emulsifier 
which converts a white paste into a more appealing product for application on the skin. Aluminum is a 
highly toxic metal, and is known to readily enter cells. It binds with calmodulin with an affinity that is 
an order of magnitude higher than that of calcium [213]. Thus, it can be anticipated that these 
aluminum-containing products will significantly interfere with the skin’s ability to produce Ch-S, 
mediated by eNOS, in addition to the direct effect of blockage of UV radiation. Furthermore, retinoic 
acid (vitamin A), which is widely present in sunscreen, inhibits cholesterol sulfate synthesis by 
epithelial squamous cells [214], and it has been shown to promote photocarcinogenesis in mice [215]. 
Thus, we propose that the current widespread practice of aggressive use of sunscreen should be abolished. 
10. Conclusions 
In this paper, we have developed an argument which proposes that systemic deficiency in the 
supply of cholesterol sulfate to the tissues can lead to both diabetes and cardiovascular disease. It is 
predicated on the assumption that eNOS is a moonlighting enzyme, and that its most significant role is 
to catalyze sulfate formation in the skin with assistance from sunlight. We have advanced many 
arguments, backed by the available literature, to support our hypothesis. First of all, it is noteworthy 
that several cell types known to synthesize functional eNOS have roles, namely the synthesis of 
heparan sulfate and/or cholesterol sulfate, that justify a compelling need for sulfate. A very strong 
argument comes from considering the role of eNOS in erythrocytes (RBCs), which would be unable to 
protect hemoglobin from binding to any synthesized NO, neutralizing the effects of both. Secondly, we 
have shown how the activities taking place in cardiovascular plaque can be framed as an attempt to 
produce cholesterol sulfate from the substrates homocysteine thiolactone and oxidized LDL. We 
discuss the various roles played by endothelial cells, macrophages, RBCs, and platelets in carrying out 
this task.  
Thirdly, HSPGs, with a very high turnover rate, are plausibly a buffer where glucose can be 
temporarily stored pending its breakdown to produce ATP. The loss of this buffering capability due to 
impaired sulfate supply can plausibly lead to insulin resistance. We have also shown how a switch 
from sulfate to nitrate production on the part of eNOS can be viewed as a pathological response to 
calcium entry, mediated by a problem with ion leaks brought on by membrane cholesterol deficiency. 
Finally, we showed that excessive nitric oxide synthesis leads to impaired autophagy, a direct 
consequence of the requirement for HSPG endocytosis to support proteolytic activities in the lysosome.  
If the inferences drawn here are correct, they suggest that diabetes and cardiovascular disease 
should be treated differently than is presently common. Treatment plans aimed at reducing serum 
cholesterol levels are inappropriate, and the practice of sun avoidance, or, more urgently, the common 
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use of sunscreen, should be avoided. On the positive side, the recommended diet should include 
abundant sources of sulfur, zinc and cobalamin.  
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